MedTrace Logo

Accurate Clinical Study of Medication in Patients With Depression Via Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) of Venlafaxine

NCT04207385 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-12-20

No results posted yet for this study

Summary

This study evaluates the efficacy of PGx-guided medication in patients with depression treated with Venlafaxine and the efficacy of the combination of PGx and TDM in patients with depression treated with Venlafaxine. Half of participants will receive PGx-guided treatment, while the other half will receive routine treatment. After the 8th week, the PGx-guided treatment group would be randomly divided into two groups. Of which, half of participants will receive the combination of PGx and TDM, and the other half will receive PGx -guided medication only.

Conditions

Interventions

DIAGNOSTIC_TEST

pharmacogenomics

pharmacogenomics

DIAGNOSTIC_TEST

pharmacogenomics & therapeutic drug monitoring

pharmacogenomics \& therapeutic drug monitoring

DRUG

Venlafaxine

Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Huaning Wang · Deputy Chief Physician

  • Ping Zhou · Attending Physician

  • Yihuan Chen · Attending Physician

  • Huizhen Lu · Resident Physician

  • Qinghong Yan · Nurse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2021-08-31
Completion
2021-11-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04207385 on ClinicalTrials.gov